Press review
The essentials of recent medical publications, unpacked by our newsroom into a clear, sourced digest, specialty by specialty.
OncologyBeyond mammography: new evidence for dense breast screening
By Carolina Lima | Published on October 17, 2025 | 3 min readBreast cancer screening is a cornerstone of early detection, but for women with dense breast tissue, traditional mammography often falls short. To address this challenge, the Breast Screening—Risk Adapted Imaging for Density (BRAID) trial, recently published in The Lancet, offers promising evidence on whether supplemental imaging can bri
OncologyA heterogeneous cancer, evolving management
By Ana Espino | Published on October 16, 2025 | 2 min readMetastatic breast cancer (MBC) remains an incurable disease with highly heterogeneous clinical forms. Despite recent advances, standard treatments—hormone therapy, chemotherapy, and immunotherapy—have limitations in the face of secondary resistance, genetic variability of tumors, and the progressive exhaustion of therapeutic options. In thi
OncologyCan a plant-based diet slow tumor progression by limiting amino acids?
By Lila Rouland | Published on October 16, 2025 | 3 min readMetastatic breast cancer relies heavily on amino acids for its growth and survival. These essential nutrients can be synthesized or absorbed directly from circulating serum, making them an attractive metabolic target. While enzymatic inhibition of amino acid biosynthetic pathways has shown limited success in clinical settings, reducing di
OncologyMetastatic breast cancer: can plants change the game?
By Ana Espino | Published on October 15, 2025 | 2 min readMetastatic breast cancer (MBC) represents the most advanced stage of the disease and remains incurable despite major therapeutic progress. It is responsible for the majority of breast cancer–related deaths. Current treatments—hormone therapy, chemotherapy, and immunotherapy—extend survival but do not eliminate the disease, while causing sig
Endocrinology and MetabolismFasting hyperglycemia: a silent cancer risk factor?
By Ana Espino | Published on October 15, 2025 | 2 min readFasting hyperglycemia (FHG)—defined as elevated blood glucose levels outside of meals—is a common condition, particularly among individuals with type 2 diabetes or metabolic syndrome. Its role in the development of cardiovascular diseases is well established, but its involvement in oncogenesis remains controversial and poorly understood. Am
OncologyKeep moving... and going the distance after cancer?
By Ana Espino | Published on October 13, 2025 | 3 min readWith the growing number of cancer survivors, care no longer ends with remission. Maintaining quality of life has become a key issue, notably through physical activity, which is recognized for its beneficial effects on fatigue, physical function, mood, and even risk of recurrence. However, while exercise interventions during treatment yield
OncologyTrastuzumab Deruxtecan: a new hope for HER2-mutated triple-negative breast cancers without HER2 expression
By Lila Rouland | Published on October 12, 2025 | 3 min readThe HER2 receptor (ERBB2) is a transmembrane protein with tyrosine kinase activity, involved in cell proliferation, tumor invasion, and angiogenesis. Its overexpression has historically been associated with a poor prognosis in breast cancer. HER2-targeted therapies, such as trastuzumab and its antibody-drug conjugates (ADCs), have profoun
OncologyTargeting to treat better?
By Ana Espino | Published on October 11, 2025 | 3 min readBreast cancer is the most common cancer among women worldwide. It is characterized by marked biological heterogeneity and often unpredictable evolution. Although advances in conventional treatments have improved overall survival, advanced and metastatic forms remain associated with a poor prognosis. Traditional approaches, especially chemot
OncologyASC: chameleon cells in action?
By Ana Espino | Published on October 10, 2025 | 3 min readAdipose tissue–derived stromal cells (ASC) play a key role in many physiopathological processes, ranging from tissue repair to immune regulation and chronic inflammatory responses, as observed in metabolic diseases, fibrosis, and certain cancers. Long considered a homogeneous population, these cells actually display marked heterogeneity, bo
OncologyWhen AI reads between the cells
By Ana Espino | Published on october 9, 2025 | 3 min read#AI #BreastCancer #BreastCancerAwareness Breast cancer is a heterogeneous disease, and some aggressive forms require neoadjuvant therapy (NAT) before surgery. This treatment aims to reduce tumor size, improve surgical resection, and assess tumor sensitivity to the therapeutic agents used. However, the response to NAT varies greatly from one
OncologyNano-spies against breast cancer?
By Ana Espino | Published on october 8, 2025 | 3 min read#BreastCancer #QuantumDots #QD #BreastCancerAwareness Breast cancer remains the leading cause of cancer-related death among women worldwide. Despite progress in screening and treatment, many aggressive forms (triple-negative, HER2+) continue to evade conventional therapies. The main limitations lie in the lack of specificity of diagnostic ag
OncologyEugenol: clove against cancer?
By Ana Espino | Published on october 7, 2025 | 3 min read#Oncology #Eugenol #Phenol Cancer is one of the leading causes of death worldwide, characterized by uncontrolled cell proliferation, metastasis, and resistance to treatment. Despite progress in targeted therapies and immunotherapy, current treatments often remain toxic, costly, and associated with a reduced quality of life. The main challeng